News GSK and J&J lead in vaccines research – but pricing still an... GlaxoSmithKline and Johnson & Johnson are leading R&D investment in vaccines, and the field is producing the first ever vaccines for conditions such as Ebola and a range of deadly b
News J&J to work with Orthocell on new regenerative stem cell the... Multi-centre trial of Ortho-ATI technology planned for early 2017.
News Johnson & Johnson back in 'exclusive' talks to buy Actelion Deal expected to be worth around $30 billion.
News No US Remicade biosimilar until at least October Pfizer must wait until 180 day period ends, court fight ongoing.
Views & Analysis A history of Johnson & Johnson Set up by three brothers back in 1886, Johnson & Johnson continues to keep evolving
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face